Private Advisor Group LLC Lowers Stock Position in Haleon plc (NYSE:HLN)

Private Advisor Group LLC cut its holdings in Haleon plc (NYSE:HLN) by 2.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,234 shares of the company’s stock after selling 1,393 shares during the period. Private Advisor Group LLC’s holdings in Haleon were worth $510,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Clearbridge Investments LLC increased its position in shares of Haleon by 44.6% during the 1st quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock valued at $326,415,000 after purchasing an additional 11,865,076 shares during the last quarter. Martin Investment Management LLC lifted its stake in shares of Haleon by 12,018.4% during the 1st quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock worth $37,893,000 after purchasing an additional 4,426,375 shares during the last quarter. Sculptor Capital LP lifted its stake in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after purchasing an additional 3,592,000 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Haleon by 95.5% in the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after buying an additional 954,622 shares during the last quarter. Finally, Raymond James & Associates raised its stake in Haleon by 14.7% in the second quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock valued at $33,205,000 after buying an additional 515,651 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

HLN stock opened at $9.76 on Tuesday. The business has a fifty day moving average of $10.23 and a two-hundred day moving average of $9.27. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market cap of $44.18 billion, a price-to-earnings ratio of 28.85, a price-to-earnings-growth ratio of 2.83 and a beta of 0.30. Haleon plc has a 52-week low of $7.89 and a 52-week high of $10.80.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group lowered Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank assumed coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Morgan Stanley lifted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.